RxSight (RXST) Invested Capital (2020 - 2023)

RxSight (RXST) has reported Invested Capital for 4 consecutive years, with $160.4 million the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Invested Capital rose 23.29% year-over-year to $160.4 million; the trailing twelve-month figure through Dec 2023 stood at $160.4 million (up 23.29% YoY), and the FY2023 full-year result was $160.4 million, up 23.29% from the prior year.
• Invested Capital slipped to $160.4 million in Q4 2023 per RXST's latest filing, from $161.5 million in the prior quarter.
• Across five years, Invested Capital topped out at $190.5 million in Q3 2021 and bottomed at -$406.2 million in Q4 2020.
• Historically, Invested Capital has averaged $80.0 million across 4 years, with a median of $160.9 million in 2023.
• The widest YoY moves for Invested Capital: up 155.38% in 2022, down 27.67% in 2022.
• Over 4 years, Invested Capital stood at -$406.2 million in 2020, then surged by 143.82% to $178.0 million in 2021, then fell by 26.93% to $130.1 million in 2022, then grew by 23.29% to $160.4 million in 2023.
• According to Business Quant data, Invested Capital over the past three periods registered $160.4 million, $161.5 million, and $182.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.